Literature DB >> 33282462

Dose-response model for severe late laryngeal toxicity after stereotactic body radiation therapy for previously-irradiated head and neck cancer.

Diane C Ling1, John A Vargo1, Rachel J Grimm2, Brian J Gebhardt1, David A Clump1, Robert L Ferris3, James P Ohr4, Dwight E Heron1.   

Abstract

We sought to evaluate the association between larynx dose and risk of severe late laryngeal toxicity in patients undergoing re-irradiation SBRT for recurrent HNC. Fifty-five patients with an intact larynx underwent re-irradiation SBRT to a median dose of 44 Gy in 5 fractions. Five (41.7%) patients treated for a laryngeal/hypopharyngeal recurrence experienced late grade ≥3 laryngeal toxicity, compared to 0.0-7.1% for other sites. Logistic dose-response models were created to predict risk of severe late laryngeal toxicity, including dysphagia and airway compromise. According to the model, the risk of severe laryngeal toxicity with a larynx D5cc of 5 Gy is 5.8% (95% CI 2.9-9.9%) and rises to 11.4% with a D5cc of 20 Gy and 25.3% with a D5cc of 40 Gy. In patients with a laryngeal/hypopharyngeal recurrence, SBRT planning should carefully assess the dose to laryngeal structures given these dose findings, and SBRT should be approached with significant caution in such patients.
© 2020 Old City Publishing, Inc.

Entities:  

Keywords:  SBRT; dose-response; head and neck cancer; late toxicity; re-irradiation

Year:  2020        PMID: 33282462      PMCID: PMC7717091     

Source DB:  PubMed          Journal:  J Radiosurg SBRT


  14 in total

1.  Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.

Authors:  Gregory T Wolf; Susan Gross Fisher; Waun Ki Hong; Robert Hillman; Monica Spaulding; George E Laramore; James W Endicott; Kenneth McClatchey; William G Henderson
Journal:  N Engl J Med       Date:  1991-06-13       Impact factor: 91.245

2.  Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival.

Authors:  Henry T Hoffman; Kimberly Porter; Lucy H Karnell; Jay S Cooper; Randall S Weber; Corey J Langer; Kie-Kian Ang; Greer Gay; Andrew Stewart; Robert A Robinson
Journal:  Laryngoscope       Date:  2006-09       Impact factor: 3.325

3.  Reexamining the treatment of advanced laryngeal cancer.

Authors:  Kerry D Olsen
Journal:  Head Neck       Date:  2010-01       Impact factor: 3.147

4.  Early Closure of a Phase 1 Clinical Trial for SABR in Early-Stage Glottic Cancer.

Authors:  Byung-Hee Kang; Tosol Yu; Jin Ho Kim; Jong Min Park; Jung-In Kim; Eun-Jae Chung; Seong Keun Kwon; Ji-Hoon Kim; Hong-Gyun Wu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-03-14       Impact factor: 7.038

5.  Phase 1 Fractional Dose-Escalation Study of Equipotent Stereotactic Radiation Therapy Regimens for Early-Stage Glottic Larynx Cancer.

Authors:  David J Sher; Robert D Timmerman; Lucien Nedzi; Chuxiong Ding; Nhat-Long Pham; Bo Zhao; Baran D Sumer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-03-14       Impact factor: 7.038

6.  Risk of Severe Toxicity According to Site of Recurrence in Patients Treated With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer.

Authors:  Diane C Ling; John A Vargo; Robert L Ferris; James Ohr; David A Clump; Wai-Ying Wendy Yau; Umamaheswar Duvvuri; Seungwon Kim; Jonas T Johnson; Julie E Bauman; Barton F Branstetter; Dwight E Heron
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-07-01       Impact factor: 7.038

7.  The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy.

Authors:  Jean-Claude M Rwigema; Dwight E Heron; Robert L Ferris; Regiane S Andrade; Michael K Gibson; Yong Yang; Cihat Ozhasoglu; Athanassios E Argiris; Jennifer R Grandis; Steven A Burton
Journal:  Am J Clin Oncol       Date:  2011-08       Impact factor: 2.339

8.  Carotid Dosimetry and the Risk of Carotid Blowout Syndrome After Reirradiation With Head and Neck Stereotactic Body Radiation Therapy.

Authors:  Brian J Gebhardt; John A Vargo; Diane Ling; Brianna Jones; Mary Mohney; David A Clump; James P Ohr; Robert L Ferris; Dwight E Heron
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-12-05       Impact factor: 7.038

9.  Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.

Authors:  Corey J Langer; Jonathan Harris; Eric M Horwitz; Nicos Nicolaou; Merrill Kies; Walter Curran; Stuart Wong; Kian Ang
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

10.  Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

Authors:  Arlene A Forastiere; Qiang Zhang; Randal S Weber; Moshe H Maor; Helmuth Goepfert; Thomas F Pajak; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Wade Thorstad; Henry Wagner; John F Ensley; Jay S Cooper
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

View more
  1 in total

1.  Effect of COVID-19 Pandemic on Gynecological Cancer Radiation During Complete Nationwide Lockdown: Observations and Reflections From Tertiary Care Institute in India.

Authors:  Abhishek Shinghal; Sonz Paul; Supriya Chopra; Lavanya Gurram; Libin Scaria; Satish Kohle; Priyanka Rane; Dheera A; John Puravath; Jivanshu Jain; Jamema Swamidas; Jaya Ghosh; Sudeep Gupta; Sushmita Rath; Sarbani Ghosh Laskar; Jai Prakash Agarwal
Journal:  Adv Radiat Oncol       Date:  2021-05-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.